Mocetinostat, a histone deacetylase inhibitor, demonstrated selective killing of senescent chondrocytes in both immortalized TC28a2 cell lines and primary human knee cartilage cells while sparing healthy cells. The compound induced apoptosis specifically in aging cells and modulated inflammation-related genes, including the NF-κB pathway. This selective toxicity represents a promising senolytic mechanism for osteoarthritis treatment. The discovery addresses a critical gap in musculoskeletal aging research where accumulating senescent cells drive joint degeneration. Unlike broad anti-inflammatory approaches, senolytics offer precision targeting of the cellular drivers of age-related joint disease. However, the findings remain preliminary, confined to cell culture systems without animal or clinical validation. The compound's safety profile and dosing parameters for humans remain undefined. Additionally, the long-term consequences of clearing senescent cells from joint tissues require investigation, as these cells may serve protective functions. While mechanistically intriguing, translating this senolytic concept from cultured chondrocytes to effective osteoarthritis therapy represents a substantial development challenge requiring extensive preclinical and clinical testing.